Human Plasma IgM Purification Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of high-purity, high-concentration polyclonal IgM pharmaceutical compositions from human plasma is challenging due to IgM's tendency to self-associate, leading to aggregate formation and potential immunogenic risks, as well as the need to reduce isoagglutinin titers to prevent blood type mismatch agglutination/hemolysis.
Innovation Solution
A process involving polyethylene glycol precipitation, ceramic hydroxyapatite chromatography, affinity chromatography to reduce isoagglutinins, nanofiltration with arginine to inhibit self-association, and ultrafiltration/diafiltration to minimize aggregate formation and concentrate IgM, ensuring a product with >97% purity and <10% aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used to obtain IgM from human plasma, then IgM can be extracted, but the purity is low (only 12% IgM in Pentaglobin) and aggregates form
Solution Approach 1:
The patent applies parameter changes by carefully controlling pH, ionic strength, and temperature throughout the purification process. Specific pH ranges are maintained to prevent IgM aggregation while enabling effective separation. The process uses controlled changes in these parameters to transition IgM between soluble and precipitable states, achieving high purity without aggregate formation.
Solution Approach 2:
The patent uses specific mediators including arginine as a stabilizer to prevent aggregation, and controlled precipitation agents to separate IgM from other plasma proteins. These intermediaries facilitate the purification process by mediating between the IgM molecules and the purification conditions, enabling high purity extraction while maintaining molecular integrity.
2Quantity of substance
If IgM concentration is increased for therapeutic use, then therapeutic efficacy improves, but self-association and aggregate formation increase
Solution Approach 1:
The patent applies preliminary action by adding stabilizers such as arginine before concentration steps and maintaining optimal pH conditions throughout the process. These preliminary measures prevent self-association from occurring in the first place, allowing high concentrations to be achieved without aggregate formation. The process prepares the IgM solution in advance with protective agents that remain effective during subsequent concentration.
3Adaptability or versatility
If polyclonal IgM is produced from human plasma, then therapeutic potential is achieved, but isoagglutinin titers cause blood type mismatch risks
Solution Approach 1:
The patent applies the taking out principle by specifically removing isoagglutinins from the polyclonal IgM preparation through selective purification steps. The process extracts and eliminates the harmful isoagglutinin fraction while retaining the beneficial therapeutic IgM populations, thereby reducing blood type mismatch risks while preserving therapeutic potential.
4Manufacturing precision
If multiple purification steps are implemented to achieve high purity, then IgM purity increases, but process complexity increases
Solution Approach 1:
The patent applies merging by combining multiple purification functions into integrated process steps. Rather than separate sequential operations, the method combines precipitation, filtration, and concentration steps into coordinated operations that achieve high purity while minimizing the number of discrete process units required. This reduces overall process complexity while maintaining manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a stable, high-purity IgM product with >98% pentamer content, reduced isoagglutinin titers, and minimal aggregate formation, maintaining specific binding affinity and complement activation capabilities, suitable for therapeutic use with extended stability.
Implementation Method 1
a) precipitation of said IgM using polyethylene glycol (PEG)
Implementation Method 2
precipitation of said IgM using polyethylene glycol (PEG)
Implementation Method 3
c) adsorption chromatography
Implementation Method 4
c) adsorption chromatography
Implementation Method 5
d) removing isoagglutinins A/B
Implementation Method 6
affinity chromatography specific for those IgM that bind to A/B RBC surface antigens
Implementation Method 7
e) nanofiltration
Implementation Method 8
nanofiltration with arginine to inhibit self-association
Implementation Method 9
f) ultrafiltration/diafiltration
Implementation Method 10
ultrafiltration/diafiltration to minimize aggregate formation and concentrate IgM
Data Source
AI summary
A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) includes PEG precipitation of the IgM, resuspension of the precipitated IgM; (c) performing an adsorption chromatography, removing isoagglutinins A/B, nanofiltration, and ultrafiltration/diafiltration. The precipitation can be performed at a pH between 4.5 and 6.5, and the PEG can be at a concentration between 5 (w/v) and 11% (w/v).